KalVista Pharmaceuticals: Has Potential But With Caveats

2026-03-12 11:07:25 ET

Shares of protease inhibitor concern KalVista Pharmaceuticals, Inc. ( KALV ) have moved up following FDA approval of its HAE therapy Ekterly. Since the July 2025 green light, the first oral on-demand treatment for HAE attacks has generated revenue of $49 million, already receiving patient start forms from ~20% of U.S. patient population. With likely one year plus of blue sky before an oral competitor from Pharvaris ( PHVS ) and a single-administration functional cure from Intellia ( NTLA ) hit the market, KalVista merited another look. An analysis/recommendation follows below....

Read the full article on Seeking Alpha

For further details see: